535
Views
26
CrossRef citations to date
0
Altmetric
Original Article/ Connective tissue diseases and related diseases

Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, , ORCID Icon & show all
Pages 351-356 | Received 26 Dec 2017, Accepted 08 Mar 2018, Published online: 09 Apr 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Ichiro Kobayashi, Shinji Akioka, Norimoto Kobayashi, Naomi Iwata, Shunichiro Takezaki, Haruna Nakaseko, Satoshi Sato, Yutaka Nishida, Tomo Nozawa, Yuichi Yamasaki, Kazuko Yamazaki, Satoru Arai, Ichizo Nishino & Masaaki Mori. (2020) Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Modern Rheumatology 30:3, pages 411-423.
Read now
Nodoka Sakurai, Ayako Hino-Shishikura, Tomo Nozawa, Hiroyuki Kamide, Asami Ohara, Kenichi Nishimura, Masako Kikuchi, Ryoki Hara, Masaaki Mori & Shuichi Ito. (2019) Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. Modern Rheumatology 29:5, pages 808-813.
Read now
Naomi Iwata, Haruna Nakaseko, Toaki Kohagura, Ryuhei Yasuoka, Naoki Abe, Shinji Kawabe, Shiro Sugiura & Yoshinao Muro. (2019) Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. Modern Rheumatology 29:5, pages 802-807.
Read now
Ran Nakashima. (2018) Clinical significance of myositis-specific autoantibodies. Immunological Medicine 41:3, pages 103-112.
Read now

Articles from other publishers (22)

Ozgur C. Kilinc & Serdal Ugurlu. (2023) Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review. Autoimmunity Reviews 22:12, pages 103464.
Crossref
Charalampia Papadopoulou, Christine Chew, Meredyth G. Ll. Wilkinson, Liza McCann & Lucy R. Wedderburn. (2023) Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nature Reviews Rheumatology 19:6, pages 343-362.
Crossref
Charles-Antoine Dallevet, Olivier Benveniste & Yves Allenbach. (2023) Pathogenesis and Treatment in IMNM. Current Treatment Options in Rheumatology 9:2, pages 32-48.
Crossref
Seher Sener, Ezgi Deniz Batu, Seher Sari, Muserref Kasap Cuceoglu, Adalet Elcin Yildiz, Beril Talim, Ustun Aydingoz, Seza Ozen & Goknur Haliloglu. (2023) A Child with Refractory and Relapsing Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Myopathy: Case-Based Review. Journal of Neuromuscular Diseases 10:2, pages 279-291.
Crossref
Kentaro Nishi, Masao Ogura, Naotaka Tamai, Masafumi Gima, Kentaro Ide, Goro Koinuma, Koichi Kamei & Shuichi Ito. (2022) Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. Pediatric Rheumatology 20:1.
Crossref
Angeles S. Galindo-Feria, Guochun Wang & Ingrid E. Lundberg. (2022) Autoantibodies: Pathogenic or epiphenomenon. Best Practice & Research Clinical Rheumatology 36:2, pages 101767.
Crossref
Renske G. Kamperman, Anneke J. van der Kooi, Marianne de Visser, Eleonora Aronica & Joost Raaphorst. (2022) Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review. International Journal of Molecular Sciences 23:8, pages 4301.
Crossref
Ichiro Kobayashi, Masaki Shimomura, Masahiro Ueki, Shunichiro Takezaki, Yuka Okura, Mitsuru Nawate, Masafumi Yamada, Yutaka Takahashi & Tadashi Ariga. (2022) Development of Graves’ disease during drug-free remission of juvenile dermatomyositis. Modern Rheumatology Case Reports 6:1, pages 55-58.
Crossref
Anne Schänzer, Leonie Rager, Iris Dahlhaus, Carsten Dittmayer, Corinna Preusse, Adela Della Marina, Hans-Hilmar Goebel, Andreas Hahn & Werner Stenzel. (2021) Morphological Characteristics of Idiopathic Inflammatory Myopathies in Juvenile Patients. Cells 11:1, pages 109.
Crossref
Xinning Wang, Yuchuan Ding, Zhixuan Zhou, Jun Hou, Yingjie Xu & Jianguo Li. (2021) Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. Pediatric Rheumatology 19:1.
Crossref
Alexander K.C. Leung, Joseph M. Lam, Saud Alobaida, Kin F. Leong & Alex H.C. Wong. (2021) Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management. Current Pediatric Reviews 17:4, pages 273-287.
Crossref
Takashi Kurashige. (2021) Anti-HMGCR myopathy: clinical and histopathological features, and prognosis. Current Opinion in Rheumatology 33:6, pages 554-562.
Crossref
Anaïs Nombel, Nicole Fabien & Frédéric Coutant. (2021) Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Frontiers in Immunology 12.
Crossref
Yuichi Yamasaki, Norimoto Kobayashi, Shinji Akioka, Kazuko Yamazaki, Shunichiro Takezaki, Haruna Nakaseko, Asami Ohara, Kenichi Nishimura, Yutaka Nishida, Satoshi Sato, Takayuki Kishi, Motomu Hashimoto, Masaaki Mori, Yuka Okazaki, Masataka Kuwana & Akiko Ohta. (2021) Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology 60:10, pages 4821-4831.
Crossref
Andrea Aguilar-Vazquez, Efrain Chavarria-Avila, Oscar Pizano-Martinez, Alejandra Ramos-Hernandez, Lilia Andrade-Ortega, Edy-David Rubio-Arellano & Monica Vazquez-Del Mercado. (2021) Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review. Frontiers in Immunology 12.
Crossref
Naoko Okiyama. (2021) Clinical Features and Cutaneous Manifestations of Juvenile and Adult Patients of Dermatomyositis Associated with Myositis-Specific Autoantibodies. Journal of Clinical Medicine 10:8, pages 1725.
Crossref
Ahmad Adebayo Irekeola, Rafidah Hanim Shueb, Engku Nur Syafirah E. A. R.Yusuf Wada, Zaidah Abdul Rahman, Suhana Ahmad, Rohimah Mohamud, Norhafiza Mat Lazim & Chan Yean Yean. (2021) Prevalence of Nasopharyngeal Carcinoma in Patients with Dermatomyositis: A Systematic Review and Meta-Analysis. Cancers 13:8, pages 1886.
Crossref
Gulnara Mamyrova, Takayuki Kishi, Min Shi, Ira N Targoff, Adam M Huber, Rodolfo V Curiel, Frederick W Miller & Lisa G Rider. (2021) Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology 60:4, pages 1839-1849.
Crossref
Nele Van Horebeek, Jean-Baptiste Vulsteke, Xavier Bossuyt, Kristl G. Claeys, Doreen Dillaerts, Koen Poesen, Jan Lenaerts, Philip Van Damme, Daniel Blockmans, Petra De Haes & Ellen De Langhe. (2021) Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review. Seminars in Arthritis and Rheumatism 51:2, pages 486-494.
Crossref
Liubing Li, Chenxi Liu, Linlin Cheng, Songxin Yan, Haizhen Chen & Yongzhe Li. (2020) Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clinical Rheumatology 40:3, pages 819-832.
Crossref
Yves Allenbach, Olivier Benveniste, Werner Stenzel & Olivier Boyer. (2020) Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nature Reviews Rheumatology 16:12, pages 689-701.
Crossref
Linqing Zhong, Zhongxun Yu & Hongmei Song. (2019) Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts. Clinical Immunology 198, pages 11-18.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.